Flagship Pioneering

News, insights, analysis and data

Flagship Pioneering overview

Flagship Pioneering contact information

Offices

marker icon55 Cambridge Parkway, Suite 800E, Cambridge, 02142, United States
Showing 1 of 1 Flagship Pioneering offices

Contacts

NameJob titleLocationEmail
Key Contact
user imageMr. Chasen Richter
Job titleAssociate Director, Strategic Investor Relations
LocationCambridge, United States
Emaillock image------
Key Contact
user imageMs. Maggie Sahlman
Job titleExecutive Partner, Head of Fundraising and Investor Relations
LocationCambridge, United States
Emaillock image----------
user imageMr. Chuck Carelli
Job titleChief Financial Officer and Executive Partner
LocationCambridge, United States
Emaillock image-----------
user imageMr. Mark Fitzpatrick
Job titlePartner and Chief Financial Officer, Growth
LocationCambridge, United States
Emaillock image---------

Flagship Pioneering fund commitments

Known fund commitments: 1

FundManagerCommitment dateCommitment size
Managerlock image---------
Commitment dateJul 2025
Commitment size-

Flagship Pioneering funds managed

Closed funds: 15

FundFund sizeClose dateStrategy
Fund sizelock image--------
Close dateNov 2024
Strategylock image-----
Fund sizelock image----------
Close dateJun 2021
Strategylock image-----------
Fund sizelock image---------
Close dateMar 2020
Strategylock image----------

Stories that mention Flagship Pioneering

Side Letter: PE hires a politician

Rishi Sunak's former deputy prime minister has joined forces with a UK private equity firm. Plus: Coller Capital is getting in on the evergreen action; and AXA IM is reaping the rewards of opening its NAV unit to third-party capital. Here's today's brief, for our valued subscribers only.

MassPRIM strengthens VC connections

The pension fund made $111m of commitments across three private equity funds.

DPERS approves $80 million in commitments

The US pension fund has backed two venture capital funds.

VC-backed IPOs dry up in Q1

There was a 65% drop in IPOs in Q1 backed by venture capital funds, but biotech companies were well represented.